Identification of Early Markers for ALS

Although several molecules have been proposed as biomarker candidates, a clinically established signature for an early or even premotor diagnosis of ALS is not available. Due to the already advanced, disease stage at the time of diagnosis as well as rapid disease progression, an early diagnosis is mandatory for efficacious disease-modifying therapies. In this project, the investigators will develop a clinical molecular fingerprint of PGMC that will provide insight into the molecular pathogenesis of ALS and allow earlier diagnosis.

NCT Number	NCT07213440
Lead Sponsor	Institut National de la Santé Et de la Recherche Médicale, France Collaborators: Technical University of Munich
Conditions	Amyotrophic Lateral Sclerosis (ALS)
Enrollment	60 participants
Start Date	2024-09-30
Primary Completion	2027-04 (estimated)
Study Completion	2027-04 (estimated)
Updated on ClinicalTrials.gov	2026-07-07